| Company/Division name | Novo Nordisk |
| Type of work | Manufacturing |
| If manufacturing, is the company an OEM? | Yes |
| Reshoring category: | Transplant |
| Total number of jobs (added or to be added): | 700 |
| Year reshoring announced: | 2015 |
| Year reshoring implemented or to be implemented: | 2015 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 1200 |
| Country(ies) from which reshored: | Denmark |
| City reshored to: | Clayton |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Drug, insulin ingredients |
| What non-domestic negative factors made offshoring less attractive? | Regulatory compliance |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Skilled workforce availability/training |
